Working... Menu

Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00775281
Recruitment Status : Completed
First Posted : October 20, 2008
Last Update Posted : April 27, 2010
Information provided by:
University Hospital Inselspital, Berne

Brief Summary:
Interstitial cystitis (IC)/chronic pelvic pain syndrome (CPPS) is a clinical syndrome of pelvic pain and/or urinary urgency/frequency in absence of a specific cause such as bacterial infection or damage to the bladder. The pathogenetic mechanisms of IC/CPPS are as yet undefined and it is largely this lack of knowledge, which precludes a systematic therapeutic approach. Experimental evidence, including results from the animal models of cystitis and the knock-out mice, indicate a participation of tachykinin receptors, especially the NK1R, in neurogenic inflammation, which is considered an important element of the IC complex. However, there is very scant information about the molecular mechanisms of IC in humans, or of the types of receptors, which participate in neurogenic inflammation. Based on our molecular biological know-how and the clinical expertise, we propose to investigate the role of the tachykinin and bradykinin receptors and their signalling partners in CPPS and bladder dysfunction in humans.

Condition or disease
Overactive Bladder Painful Bladder Syndrome Chronic Pelvic Pain Syndrome Cystitis, Interstitial

Detailed Description:

Although IC has been recognised for more than a century, its pathophysiology remains a mystery, and as a consequence the treatment of IC is largely empirical. A multitude of mechanisms of the disease have been postulated ranging from neuroinflammatory to autoimmune or possibly infectious or toxic agents. Newer studies have hinted towards a genetic basis of the disease, but in most hypotheses an inflammatory component of some kind is involved and many findings support this theory. An often-cited hypothesis is the leaky epithelium. The healthy bladder is coated with a thin mucinous substance bladder surface mucin, which is composed of numerous sulfonated glycosaminoglycans and glycoproteins. In IC patients, in contrast to controls, as well as in some animal models of IC, qualitative changes to this surface layer have been observed (Lilly et al, 1990., Moskowitz et al, 1994). An initiating event (toxin) may lead to functional changes and increased permeability. This in turn leads to nerve sensitisation and possibly up-regulation. There is increasing evidence that the progression of IC is accompanied by a significant up-regulation of sensory nerves in the bladder (Letourneau, 1996). Nerve growth factor (NGF), a neurotropin that sensitises nociceptor fibres, was reported to be increased in bladders of IC patients (Lowe, 1997), and application of NGF in Wistar rats acutely induced bladder hyperactivity (Chuang, 2001). Sensory nerves in neurogenic inflammation secrete inflammatory mediators such as Substance P (SP), a nociceptive neurotransmitter in the central and peripheral nervous system. Increased amounts of the released Substance P have been found in the urine of IC patients (Hohenfellner, et al,1992, Pang et al., 1995, Pang et al., 1996), the concentration of Substance P reflecting the patients' degree of pain (Chen et al., 1999). Substance P and related tachykinins (TKs) mediate a variety of physiological processes in the genitourinary, pulmonary and gastrointestinal tract through stimulation of NK1 and NK2 receptors. Pre-clinical evidence obtained through use of selective tachykinin receptor antagonists indicates that endogenous tachykinins are involved in regulation of smooth muscle contraction, vasodilation, water metabolism and inflammation. Recently it was shown that mRNA encoding for SP receptor NK1 is in-creased in the bladder biopsies from patients with interstitial cystitis (Marchand et al., 1998). NK1R mRNA was found in detrusor muscle, urothelium and vascular structures, and the endothelial NK1R were markedly increased. SP binding to NK1R on endothelial cells results in vasodilation, plasma extravasation, cytokine release and activation and infiltration of immune cells, all characteristic of IC. Experiments with the NK1R knockout mice allowed for the first time to demonstrate the obligatory requirement of NK1R in cystitis and participation of these receptors in the chain of events linking mast cell degranulation and inflammation (Saban et al., 2000).

Changes in the sarcolemma, and altered expression of the tachykinin and bradykinin receptors might significantly influence the downstream signalling events leading to propagation of the symptoms of chronic pelvic pain/IC. By uncovering the link between clinical symptoms and the molecular regulation of the atypical inflammatory response, we may be able to offer novel and specific options for treatment. In the current proposal, we would like to further our studies of urinary bladder pathology, in particular the symptomatic complex of PBS/interstitial cystitis, and investigate the effect of changes in human urothelium and detrusor muscle cells on the NK1R-mediated signalling.

Biopsies from controls and PBS patients will be obtained in either general or spinal anesthesia transurethrally from the bladder dome and trigone with a biopsy tong. RNA will be extracted, and the expression levels of selected genes analyzed using Taqman real-time PCR and gene expression arrays (Applied Biosystems). Calcium imaging will be used to monitor the receptor activation and protein levels analysed by SDS-PAGE and Western Blotting. Receptor tissue distribution will be analysed by immuno-cytochemistry.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 45 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Mediators of Neurogenic Inflammation in the Urinary Tract as Key Factors in the Painful Bladder Syndrome / Interstitial Cystitis and Bladder Dysfunction
Study Start Date : October 2006
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine


Primary Outcome Measures :
  1. Receptor expression in disease states versus control [ Time Frame: at time of biospy ]

Biospecimen Retention:   Samples With DNA
cold cut bladder biopsies

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
university hospital clinic

Inclusion Criteria:

  • Clinical asymptomatic bladder function
  • Clinical urgency frequency syndrome/ overactive bladder
  • Clinical painful bladder syndrome/interstitial cystitis

Exclusion Criteria:

  • Not able to understand patient information
  • Other cause of symptoms
  • Confusable diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00775281

Layout table for location information
Dept. of Urology, Bern University Hospital
Bern, Switzerland, 3010
Sponsors and Collaborators
University Hospital Inselspital, Berne


Layout table for additonal information
Responsible Party: PD PhD K. Monastyrskaya, Institute of Anatomy, Balzerstrasse 2, 3000 Bern 9 Identifier: NCT00775281     History of Changes
Other Study ID Numbers: KEK_146_05
First Posted: October 20, 2008    Key Record Dates
Last Update Posted: April 27, 2010
Last Verified: April 2010

Keywords provided by University Hospital Inselspital, Berne:
Tachykinin receptors
Protein expression
Contractile proteins
Inflammatory proteins

Additional relevant MeSH terms:
Layout table for MeSH terms
Cystitis, Interstitial
Urinary Bladder, Overactive
Pelvic Pain
Pathologic Processes
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Neurologic Manifestations